Trial reportInflammopharmacology2025
Boswellic acids as an adjunct therapy in Parkinson's disease: a double-blind clinical trial investigating on its effects on motor symptoms and inflammatory markers.
Trial report in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) is a progressive neurodegenerative disorder characterized by postural instability, rigidity, bradykinesia, and resting tremors. Neuroinflammation has been implicated in PD pathogenesis, with inflammatory cytokines serving as potential biomarkers for disease progression and therapeutic monitoring. This study aimed to assess the effects of boswellic acids' supplementation (the main active component of Strowell®) on motor and cognitive function in PD patients, as well as its impact on inflammatory biomarkers.
methodsIn a 6-month, randomized, double-blind, placebo-controlled clinical trial, 58 PD patients were assigned to receive either boswellic acids or a placebo. Clinical assessments included the Unified Parkinson's Disease Rating Scale (UPDRS) and the Montreal Cognitive Assessment (MoCA), with comparisons to baseline scores. Inflammatory biomarkers were measured at baseline and after 1 month.
resultsAfter 6 months, UPDRS scores remained stable in the boswellic acids group but significantly worsened in the placebo group (p = 0.0008). MoCA scores showed a slight but non-significant improvement in the treatment group, while no improvement was observed in the placebo group. In addition, 1 month of boswellic acids' supplementation led to a significant reduction in plasma levels of pro-inflammatory cytokines, including IL-4, IL-1A, IL-12p70, INF-γ, IL-1β, TNF-α, IL-6, and PGE2.
conclusionThe findings suggest that boswellic acids' supplementation may help mitigate motor function decline in PD patients while exerting significant anti-inflammatory effects. These results support the potential role of boswellic acids as an adjunctive therapy for Parkinson's disease.
Indexed as
Identifiers
41037121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.